A trial of AZD1390 and radiotherapy for some types of brain tumour

Cancer type:

All cancer types
Brain (and spinal cord) tumours
Cancer spread to the brain
Secondary cancers

Status:

Open

Phase:

Phase 1

This trial is looking at AZD1390 in combination with radiotherapy. It is for people who have 1 of the following:

  • a type of brain tumour called glioblastoma multiforme, that has come back or started to grow again
  • a solid tumour Open a glossary item that has spread to the brain from elsewhere in the body
  • a specific subtype of brain tumour called glioblastoma multiforme that has just been diagnosed

More about this trial

Glioblastoma is a type of brain tumour. Glioblastoma multiforme (GBM) is one of the most common types of brain tumour in adults.

The usual treatment for glioblastoma is surgery to remove as much of the tumour as possible. After surgery, you usually have radiotherapy and chemotherapy. But sometimes the cancer comes back again.

There are a number of different treatments for cancer that has spread to the brain from another part of the body. This might include radiotherapy or chemotherapy.

Researchers are looking for ways to improve treatment for people who have:

  • glioblastoma multiforme (GBM)
  • cancer spread to the brain from elsewhere in the body

In this trial, they are looking at a drug called AZD1390 alongside radiotherapy. Radiotherapy damages cancer cells. AZD1390 stops the cancer cells repairing themselves after radiotherapy so radiotherapy works better.

This is the first time people are having AZD1390.

The aims of the trial are to:

  • find the best dose of AZD1390
  • find the best schedule of AZD1390 in combination with radiotherapy
  • see how well AZD1390 works with radiotherapy
  • learn more about the side effects of AZD1390 in combination with radiotherapy

Who can enter

The following bullet points list the entry conditions for trial. Talk to your doctor or the trial team if you are unsure about any of these. They will be able to advise you.

Who can take part

Main entry conditions

You may be able to join this trial if all of the following apply.

You:

  • have a tissue sample (biopsy) Open a glossary item available for the trial team to do some tests on
  • can swallow tablets
  • need help from time to time but can mostly look after yourself (Karnofsky performance status of 60% or more)
  • have satisfactory blood test results 
  • are willing to use 2 forms of reliable contraception during treatment and for 16 weeks afterwards if there is any chance you or your partner could become pregnant
  • are at least 18 years old and can provide consent to enter the study

As well as the main entry conditions above, the following must also apply.

To join group A, you:

  • have GBM that has come back or is getting worse and are eligible for another course of radiotherapy
  • have already had radiotherapy that finished at least 6 months ago
  • are taking medication if you have fits (seizures) and they are under control
  • are willing to take a medication during the trial to prevents fits

To join group B:

  • you have a solid tumour Open a glossary item that has spread to the brain from elsewhere in the body
  • you aren’t suitable to have a type of radiotherapy called stereotactic radiosurgery
  • you haven’t had radiotherapy to the brain
  • your solid tumour is stable and won’t need treatment for at least 2 months
  • you haven’t had radiotherapy to the lungs in the last 8 weeks
  • you haven’t had fits because of your tumour in the brain

To join group C:

  • you have a type of brain tumour called glioblastoma multiforme
  • you have a change in the expression of a gene called MGMT
  • you haven’t had seizures (fits) after surgery
  • if you have had seizures after surgery, they must be controlled with no more than 2 different types of medication to prevent fits
  • you are willing to take a medication to prevent fits

Who can’t take part

You cannot join this trial if any of these apply.

Cancer related

You:

  • have had chemotherapy or an experimental drug in the 28 days before starting treatment
  • have had drugs that can damage the lungs within the past year except carmustine or lomustine

Medical conditions

You:

  • have a severe brain injury or have had a stroke
  • have epilepsy or a history of fitting that isn’t related to the brain tumour
  • have a lung condition called interstitial lung disease or pneumonitis caused by radiotherapy
  • have a severe lung infection such as pneumonia or an uncontrolled lung condition called chronic obstructive pulmonary disease
  • have significant muscle weakness (myopathy)
  • have problems with your heart, such as a heart attack in the last 6 months, heart failure, angina that is not well controlled or an abnormal rhythm of your heart
  • have had a bleeding problem
  • have an active hepatitis B or hepatitis C infection
  • have HIV

Other

You:

  • can’t have MRI scans for any reason
  • are sensitive to AZD1390 or anything it contains
  • have taken any medication that blocks an enzyme called CYP3A4 in the 14 days before starting treatment
  • are pregnant or breastfeeding

Trial design

This is a phase 1 trial. It is taking place in the United Kingdom and the United States. The researchers plan for about 132 people to take part.

You’ll join 1 of the following 3 groups. The group you join depends on the type of brain tumour you have.

  • Group A is for people with glioblastoma that has come back or is growing again
  • Group B is for people with a solid tumour that has spread to the brain
  • Group C is for people with a specific type of glioblastoma multiforme that has just been diagnosed

Everyone will receive radiotherapy and AZD1390.  

AZD1390

AZD1390 is a tablet. In all groups, the first few people taking part have a low dose of AZD1390. The next few people will have a higher dose if they don’t have any serious side effects. And so on, until they find the best dose. This is called a dose escalation study.

You:

  • have 1 dose of AZD1390 before radiotherapy
  • have radiotherapy and some people have AZD1390 and some don’t (the trial team will tell you more about your schedule of AZD1390 and when to take it)
  • take AZD1390 once a day, every day for 2 weeks after radiotherapy finishes

During the 2 weeks after radiotherapy, the trial team will ask you to keep a diary to record each time you take AZD1390.

Radiotherapy

Before you have radiotherapy, you have a planning appointment as part of your care. This includes CT and MRI scans. The trial team will arrange this appointment for you.

You have standard radiotherapy every weekday.

This is for:

  • 2 weeks in Group A and Group B
  • 6 weeks in Group C

Samples for research

As well as routine blood tests, you have extra blood samples as part of this trial. Where possible, you give the samples at the same time as your routine blood tests. The researchers use the extra blood samples for a variety of tests.

For example, to:

  • find out what happens to AZD1390 in the body (pharmacokinetics Open a glossary item)
  • look for biomarkers Open a glossary item to find out why treatment might work for some people and not for others

You also give some extra urine samples.

The trial team will also ask to use tissue samples from previous biopsies or surgeries. But you don’t have to agree to this if you don’t want to. You can still take part in the trial.

Hospital visits

You will see a doctor and have some tests done before you can take part. These include:

  • physical examination
  • some tests to see how your nervous system works, which includes checking your muscle strength and how you follow commands
  • blood samples
  • urine samples
  • heart trace (ECG Open a glossary item)
  • CT scan and MRI scan

You take AZD1390 at the hospital before radiotherapy. You usually have it 3 hours before radiotherapy. Once you have finished radiotherapy, you will take AZD1390 at home for 2 weeks.  

You will see the trial team for a check up:

  • twice a week during the 2 weeks that you take AZD1390
  • 4 weeks after you finish radiotherapy

In group A and group C, you will have an MRI scan and check up every 8 weeks. This continues for as long as the cancer stays the same.

In group B, you will have an MRI every 4 weeks after finishing radiotherapy.

Side effects

As AZD1390 is a new drug, there may be some side effects we don’t know about yet. The trial team will monitor you during treatment and afterwards.  You’ll have a phone number to call if you are worried about anything.

The possible side effects of AZD1390 are:

  • seizures (fits)
  • lung problem such as shortness of breath, difficulty in breathing, or a cough or pain in your chest that gets worse on breathing or coughing
  • muscle pain or tenderness, stiffness, cramps or weakness
  • dark urine
  • a drop in blood cells causing an increased risk of infection, bleeding problems, tiredness and breathlessness
  • rapid or irregular heartbeats
  • low blood pressure causing light headedness, giddiness, breathlessness or fainting
  • changes in your pancreas resulting in severe tummy (abdominal) pain or tummy pain that you feel in your back
  • an increased sensitivity to sunlight

The trial team will ask you to avoid long periods in the sun, cover up, use adequate sunscreen protection and avoid tanning booths and sun beds during the trial and for 4 weeks after taking AZD1390.

We have more information about the side effects of radiotherapy to the brain.

Location

Cambridge
Glasgow
Leeds

Recruitment start:

Recruitment end:

How to join a clinical trial

Please note: In order to join a trial you will need to discuss it with your doctor, unless otherwise specified.

Please note - unless we state otherwise in the summary, you need to talk to your doctor about joining a trial.

Chief Investigator

Prof Anthony Chalmers

Supported by

AstraZeneca

Questions about cancer? Contact our information nurses

Freephone 0808 800 4040

Last review date

CRUK internal database number:

15640

Please note - unless we state otherwise in the summary, you need to talk to your doctor about joining a trial.

Around 1 in 5 people take part in clinical trials

3 phases of trials

Around 1 in 5 people diagnosed with cancer in the UK take part in a clinical trial.

Last reviewed:

Rate this page:

Currently rated: 5 out of 5 based on 1 vote
Thank you!
We've recently made some changes to the site, tell us what you think